Here is some generally directional, untied options activity that caught my eye during Thursday’s trading: 1. MU – in front of today’s fiscal Q3 earnings options volume was more than 2x average daily volume with …
Continue readingABT
VIX spot closed above 12.50 for only the second time over the past 6 weeks. Options volumes were focused on ETFs. 1. XLF – Two large opening trades: looks like 56,000 Oct 20 puts bought for …
Continue reading
Considering the start to the week, with Monday’s delayed reaction to disappointing December Jobs number, I think it’s fair to say that if we closed right here (basically unchanged from last Friday’s close), that it …
Continue reading
Abbvie has made several attempts in the past month to break above the $50 level, which it first touched in late October. The company had good Hepatitis C Treatment data in Phase III results released …
Continue reading
Abbott was one of the largest pharmaceutical companies in the world prior to its split in December 2012. The company spun off its proprietary pharmaceutical business (classic business of developing drugs for FDA approval and …
Continue readingTrade Update Nov. 30th, 2012 at 10:20 am: I walked through my thoughts this morning in the Macro Wrap on the ABT call diagonal I traded in October. In short, there are 2 reasons why …
Continue reading
Since it was a quiet overnight session, with not much new to note, I want to take a detour from the macro this morning to focus on some trade school. We use calendar spreads very …
Continue reading
It might be hard to believe, but Abbott Labs is in the elite group of companies in the world with over a $100 billion market cap. Since it’s generally viewed as a boring health care …
Continue reading
Health care is outperforming the broader S&P 500 for the second straight year, the first time in a decade that this has happened. Health care is generally known to outperform in weak markets. This year …
Continue reading